Share

Enveric Biosciences Inc. - news published 259 - readings 4.347

BACK
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs - Form 8-K

Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs Composition of matter and methods of use claims encompass EB-373, Enveric's new chemical entity psilocin prodrug being developed for the treatment of anxiety disorder CAMBRIDGE, Mass., August 28, 2023 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or ...

Continue reading
28.08.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program - Form 8-K

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program High purity of manufactured prodrug product allows Enveric and partners to ship EB-373 without being subject to restrictions required for controlled substances CAMBRIDGE, Mass., August 21, 2023 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the &quo ...

Continue reading
21.08.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program August 21, 2023 High purity of manufactured prodrug product allows Enveric and partners to ship EB-373 without being subject to restrictions required for controlled substances CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the " ...

Continue reading
21.08.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results

Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results August 14, 2023 Advanced preclinical pipeline of neuroplastogenic small-molecule therapeutics targeting neuronal atrophy to offer a first-in-class treatment of mental health disorders Secured multiple Notices of Allowance and select issuances from the United States Patent and Trademark Office (the ...

Continue reading
14.08.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results - Form 8-K

Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results ● Advanced preclinical pipeline of neuroplastogenic small-molecule therapeutics targeting neuronal atrophy to offer a first-in-class treatment of mental health disorders ● Secured multiple Notices of Allowance and select issuances from the United States Patent and Trademark Office (the "US ...

Continue reading
14.08.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced successful completion of preclinical ADME and toxicology studies conforming to earlie ...

Continue reading
24.07.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373 - Form 8-K

Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373 Absorption, distribution, metabolism, and excretion (ADME) and toxicology assays demonstrated rapid conversion of EB-373 to the active metabolite psilocin, consistent with previously reported animal pharmacokinetic (PK) studies CAMBRIDGE, Mass., July 24, ...

Continue reading
24.07.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373 - Form 8-K

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373 Orally administered EB-373 resulted in dose-dependent increase in psilocin blood concentration in pharmacokinetic (PK) animal studies, correlating to levels expected to be effective based on psilocybin data in humans Outcome of a ...

Continue reading
17.07.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogen small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced positive results from PK animal studies demonstrating oral bioavailability, rapid onset ...

Continue reading
17.07.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the development of an improved formulation of EB-373 designed to enhance the drug product's scalabilit ...

Continue reading
26.06.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)

CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that its research involving the synthesis of small molecule derivatives of psychoactive compound ...

Continue reading
07.06.2023